Exagen Inc. Form 8-K Summary
Business Context and Reporting Period
Exagen Inc. (XGN), a Delaware corporation, filed this Current Report on Form 8-K on April 28, 2023. The filing details the entry into a material definitive agreement regarding the company's existing debt facilities.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring rather than operational financial performance metrics such as revenue or profit, which are not provided in this document.
- Debt Prepayment: The Company prepaid $10.0 million of principal on its term loan.
- Interest Rate Revision: The new rate is the greater of the Wall Street Journal Prime Rate or 8.0%, plus 2.0%.
- Payment in Kind (PIK): 1.5% of the interest rate will be payable in-kind and capitalized to the principal monthly until April 1, 2026.
- Maturity Extension: The loan maturity date has been extended to December 31, 2026.
- Interest-Only Period: Extended through March 2026.
Material Changes Versus Prior Period
The Third Amendment to the Loan and Security Agreement with Innovatus Life Sciences Lending I, LP introduced several material changes to the Original Loan Agreement:
- Fee Waiver: The Prepayment Fee associated with the $10.0 million prepayment was waived.
- Covenant Relief: Revenue covenant thresholds were decreased. Additionally, the obligation to comply with the Revenue Covenant is removed for any fiscal quarter where the Company maintains a minimum cash balance equal to 50% of the aggregate principal loan amount.
- Cure Period: A cure period was added for certain covenant breaches.
- Indebtedness Definition: The definition of "Permitted Indebtedness" was revised to allow broader limits on capitalized lease obligations, finance leases, and equipment financings without prior lender consent.
Outlook, Risks, and Management Commentary
Management's actions indicate a strategic focus on liquidity preservation and covenant compliance. By extending the maturity date and interest-only period, the Company reduces near-term cash outflow requirements. The removal of revenue covenants contingent on maintaining specific cash balances provides operational flexibility. The filing does not contain specific forward-looking guidance on revenue or earnings, nor does it detail specific risks beyond the terms of the amended loan agreement.
Investor Verification Checklist
- Verify the total outstanding principal balance of the loan following the $10.0 million prepayment.
- Confirm the Company's current cash balance to assess compliance with the 50% cash balance threshold required to waive revenue covenants.
- Review the impact of the 1.5% payment-in-kind interest on the growing principal balance through April 2026.
- Examine the specific revised revenue thresholds in the attached Exhibit 10.1 to understand the new covenant requirements.